Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
Eli Lilly gains positive CHMP opinion for Foundayo (orforglipron), a new oral GLP-1 tablet for weight loss and type 2 diabetes.
Share
Why It Matters
Eli Lilly's new pill for weight and diabetes got approval support in Europe. This shows the company is winning in a popular medicine area that many people need.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.